Fluvoxamine Phase 3 Trial: How to Enroll

In a CETF-sponsored clinical trial, early treatment of COVID-19 with fluvoxamine dramatically reduced hospitalization rates by more than 90%.

The Phase 3 trial is now open to anyone in the US.

CETF's work featured on 60 Minutes

On Sunday, March 7th, 60 Minutes featured CETF in a story about using Fluvoxamine as an early treatment for COVID-19.

Watch Now

Two women talking and holding a beer mug

Medical Breakthrough

75%

Camostat Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla

Overview

We're on a mission to find an existing drug or drug combination that, when given early, reduces hospitalization and fatality rates by 75% or more.

Learn more

The Problem

Nearly all funded clinical trials today are focused on slow or ineffective solutions

New drugs/vaccines take a long time to develop and an even longer time to distribute. Some experts predict it will take many countries seven years to vaccinate 75% of their populations.

Repurposing existing drugs is much faster. Unfortunately, nearly all clinical trials of repurposed drugs have been conducted via inpatient trials

These require participants to be hospitalized before joining the trial
Viruses respond best when treated early, not late.

‍As a result, inpatient trials have had limited success because patients receive treatments too late

Learn more ›

Our Solution

Identify early treatments by funding outpatient clinical trials of the most promising existing drugs

Clinical trials ›

Promising Drugs

Learn about promising early treatment drugs such as Fluvoxamine, and the exciting clinical trial results

Learn more

Who we are

We are a team of the world’s top scientists, doctors, technologists and philanthropists working, to identify meaningful treatments for COVID-19, that could be used ASAP

Chairman of CETF SAB; immunologist and virologist working on HIV at Johns Hopkins University

Robert Siliciano, M.D., Ph.D.

Johns Hopkins University

Chairman of CETF SAB; immunologist and virologist working on HIV at Johns Hopkins University

Professor of cell biology; virologist and coronavirus expert at Johns Hopkins University

Carolyn Machamer, Ph.D.

Johns Hopkins University

Professor of cell biology; virologist and coronavirus expert at Johns Hopkins University

Professor emeritus of medicine, molecular biology/genetics and
medicine, Johns Hopkins

Stephen Desiderio, M.D, Ph.D.

Johns Hopkins University

Professor emeritus of medicine, molecular biology/genetics and
medicine, Johns Hopkins

Professor emeritus of pathology and medicine; director, University of California, San Diego Center for AIDS Research and Research Center for AIDS and HIV Infection at VA San Diego Healthcare System

Doug Richman, M.D.

University of California

Professor emeritus of pathology and medicine; director, University of California, San Diego Center for AIDS Research and Research Center for AIDS and HIV Infection at VA San Diego Healthcare System

Physician-scientist; HIV clinical trials expert, Harvard Medical School

Raj Gandhi, M.D.

Harvard University

Physician-scientist; HIV clinical trials expert, Harvard Medical School

Professor of medicine (infectious diseases), Howard Taylor Ricketts; HIV virology expert and director, HIV Translational Research Center at Northwestern

Rich D'Aquila, M.D.

Northwestern University

Professor of medicine (infectious diseases), Howard Taylor Ricketts; HIV virology expert and director, HIV Translational Research Center at Northwestern

Full scientific advisory board ›

What medical experts are saying

“I strongly support the work CETF is doing. Testing the top antiviral drugs must be our #1 priority. It is critical to raise funds to enable this testing to take place as soon as possible.”

Siddhartha Mukherjee, MD, PhD

Pulitzer Prize winning author
Researcher & Physician
Columbia University

"It's invigorating to see that CETF is working to fund COVID-19 research in a rapid and collaborative manner and focusing their resources on strategies that are likely to have the greatest immediate impact."

Chetan Bettegowda

Professor of Neurosurgery and Oncology
Johns Hopkins Medical Institutions

"We agree with CETF that preventative approaches have the best chance of alleviating suffering and death from COVID-19 and commend them for supporting these much needed lines of investigation."